Derisk high-stakes decisions with commercial strategy measurement that validates, or invalidates, your value creation priorities.

Commercial strategy data for investors and operators.

Bets on the wrong opportunities are costly

  • Commercial due diligence is expensive and time-consuming.
  • You need your value creation team working on the right opportunities, not low-ROI issues.
  • Miss multiple expansion opportunities leading up to sale, and the value goes to the buyer.
Added decision certainty
Answers in a week, not months
Realize more multiple expansion opportunities
Judgments from experts that don’t hallucinate

Remidi benchmarks a company’s commercial strategy against peers and our 800+ company database, scored on messaging, positioning, pricing, buyer experience and trust.

  • 30+ unique factors scored objectively and consistently.
  • Outside-in view of the buyer’s perspective of you and your competitors.
  • 20+ data sources: websites, review sites, quality research and more. No company work required.
  • Model weightings are optimized to correlate to successful outcomes.
4×
Companies scoring in Remidi’s top 25% are 4× more likely to become market leaders.
The scores [Remidi] got for each company were pretty damn close — [they] got the dogs right and identified where the value is. — VC General Partner
Supporting commercial due diligence with data
Validating value creation plan assumptions
Prioritizing operating resources
Finding multiple expansion pre-sale

Founder: Michael Himmelfarb

  • Global GM, Nielsen Shopper Panel
  • 3× Operating Partner, 3× CMO
  • Lehman Brothers, BlackRock
  • Wharton, Booth MBA

Past clients include

Platinum EquityMercuryEdison PartnersSerra Ventures

Financials tell you the size of the opportunity. Remidi Commercial Health Score tells you what’s achievable.


Commercial health, from the buyer’s POV. Get a data-based analysis of your target, benchmarked against peers in two weeks — before investing months in research and due diligence.

[Remidi’s] report validated that the other input we’d gotten was sound and trustworthy — and every point made sense. — Supply-chain software executive
SMB Marketing Automation Category
CompanyICP / Target buyerOverallPos.PricingBuyer Exp.Trust
StorelarkSingle-location owner4773364038
VouchlySMB service owner79938410060
TendlySMB, 20–100 staff74100526075
PerchMulti-location brands7193323590
ConveyLocal, going upmarket66100283575
Peer average—7296495875

Prioritize operating resource focus and future investments by mapping fund portfolio Financial Health (opportunity) against Commercial Health (addressability).

They let us use data to rank the whole portfolio and replace month-long analyst work with faster screening. — Value Creation lead, mid-market PE
Fund IV Portfolio Opportunity Analysis MULTIPLE EXPANSION HIGH PERFORMER REVENUE GROWTH EXECUTION CHECK Endorsely Medisync Herdwise FarmGate FieldIQ BuildLens Storelark CropSignal Remidi Commercial Health Score → Revenue growth ’25 → ’26

Compare and fine-tune the current VCP with a 90-day plan, designed by expert operators based on the data — not hallucination.

Showcase.com 30-60-90 Value Creation Action Plan
Days 0–30 · Build trust

Trust & Credibility 38 (peer avg 75)

Evidence: Peers carry 2,000–4,000 G2 reviews; Storelark shows almost none — despite 25,000+ businesses served.

Days 30–60 · Focus GTM

Messaging & Positioning 73 (peer avg 96)

Evidence: Perch and Convey are vacating the single-location owner as they move upmarket — the lane Storelark is best-positioned to own.

Days 60–90 · Simplify buying

Pricing & Buyer Exp. 36/40 (peer 49/58)

Evidence: Vouchly tops the set on this low-friction entry; Convey and Perch stay quote-gated.

Reach out to learn more about how Remidi derisks decisions.